Abstract
In spite of the unquestionable positive impact of HAART in the treatment of HIV infection, the discovery and development of novel agents directed towards other targets of the replicative cycle of the virus that differ from those targeted by the clinically approved drugs, emerges nowadays as an imperative need. The blockade of HIV entry is a highly promising strategy against the pathogen and glycoprotein gp120 is a central actor in this process. This review discusses the current status in the research of anti-HIV agents targeting specifically the envelope protein gp120. The diverse approaches devoted to the achievement of therapeutic agents against gp120 currently under study are organized and analyzed critically according to their specific mechanism of inhibition and structural features.
Keywords: AIDS, human immunodeficiency virus (HIV), HIV entry, attachment inhibitors, polyanions, carbohydrate-binding agents (CBAs), CD4 binding site, co-receptor binding site, glycoprotein gp120
Current Medicinal Chemistry
Title:Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy
Volume: 20 Issue: 6
Author(s): A. Flores and E. Quesada
Affiliation:
Keywords: AIDS, human immunodeficiency virus (HIV), HIV entry, attachment inhibitors, polyanions, carbohydrate-binding agents (CBAs), CD4 binding site, co-receptor binding site, glycoprotein gp120
Abstract: In spite of the unquestionable positive impact of HAART in the treatment of HIV infection, the discovery and development of novel agents directed towards other targets of the replicative cycle of the virus that differ from those targeted by the clinically approved drugs, emerges nowadays as an imperative need. The blockade of HIV entry is a highly promising strategy against the pathogen and glycoprotein gp120 is a central actor in this process. This review discusses the current status in the research of anti-HIV agents targeting specifically the envelope protein gp120. The diverse approaches devoted to the achievement of therapeutic agents against gp120 currently under study are organized and analyzed critically according to their specific mechanism of inhibition and structural features.
Export Options
About this article
Cite this article as:
Flores A. and Quesada E., Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy, Current Medicinal Chemistry 2013; 20 (6) . https://dx.doi.org/10.2174/0929867311320060002
DOI https://dx.doi.org/10.2174/0929867311320060002 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders
Current Topics in Medicinal Chemistry Retromer's Role in Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases
Current Protein & Peptide Science A Review of Intrahepatic Cholestasis of Pregnancy
Current Women`s Health Reviews The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence
Current Pharmaceutical Design The Role of LH in Ovarian Stimulation
Current Pharmaceutical Biotechnology Current Genomics in Cardiovascular Medicine
Current Genomics Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration
Central Nervous System Agents in Medicinal Chemistry Therapeutic Potential of Resveratrol in Diabetic Nephropathy According to Molecular Signaling
Current Molecular Pharmacology Dyslipidemia, Vascular Atheroma and Statins
Current Vascular Pharmacology Progress and Outlooks in a Genetic Absence Epilepsy Model (WAG/Rij)
Current Medicinal Chemistry Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Prevention of Sexually Transmitted Human Immunodeficiency Virus (HIV) Infection in Adolescents
Current HIV Research Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Toxicity and Tolerability of <sup>177</sup>Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study
Current Radiopharmaceuticals Selective Removal of Macrophages in Atherosclerotic Plaques as a Pharmacological Approach for Plaque Stabilization: Benefits Vs. Potential Complications
Current Vascular Pharmacology Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology